Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;43(2):183-9.
doi: 10.1097/MPA.0000000000000088.

The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies

Chang Moo Kang  1 , Michele L Babicky, Andrew M Lowy
Affiliations
Review

The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies

Chang Moo Kang et al. Pancreas. 2014 Mar.

Abstract

Pancreatic cancer remains a devastating disease with a mortality rate that has not changed substantially in decades. Novel therapies are therefore desperately needed. The RON receptor tyrosine kinase has been identified as an important mediator of KRAS oncogene addiction and is overexpressed in the majority of pancreatic cancers. Preclinical studies show that inhibition of RON function decreases pancreatic cancer cell migration, invasion, and survival and can sensitize pancreatic cancer cells to chemotherapy. This article reviews the current state of knowledge regarding RON biology and pancreatic cancer and discusses its potential as a therapeutic target.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors have no conflicts of interest to disclose

Figures

Figure 1
Figure 1. Morphologic structure of the RON receptor tyrosine kinase and its potential downstream signaling pathways
RON is a trans-membrane receptor composed of a disulfide-linked 40 kDa α-chain and a 150 kDa β-chain. RON contains multiple extracellular domains including SEMA, PSI (Plexin, Semaphorin, Integrins), and four IPT (Immunoglobulin-like folds shared by Plexins and Transcriptional factors). The kinase domain with catalytic activity is located in the intracellular portion of the protein.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. - PubMed
    1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;36:1605–1617. - PubMed
    1. Katz MH, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:836–847. - PMC - PubMed
    1. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303) J Clin Oncol. 2010;28:3617–3622. - PMC - PubMed
    1. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605–3610. - PMC - PubMed

MeSH terms